Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 14 08 2018
accepted: 03 10 2018
pubmed: 29 10 2018
medline: 14 6 2019
entrez: 29 10 2018
Statut: ppublish

Résumé

Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction, and aberrant cell signaling. Given the links between lifestyle, AGEs, and disease, we examined the association between dietary-AGEs and breast cancer. We evaluated AGE levels in bio-specimens from estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer patients, examined their role in therapy resistance, and assessed the ability of lifestyle intervention to reduce circulating AGE levels in ER+ breast cancer survivors. An association between ER status and AGE levels was observed in tumor and serum samples. AGE treatment of ER+ breast cancer cells altered ERα phosphorylation and promoted resistance to tamoxifen therapy. In a proof of concept study, physical activity and dietary intervention was shown to be viable options for reducing circulating AGE levels in breast cancer survivors. There is a potential prognostic and therapeutic role for lifestyle derived AGEs in breast cancer. Given the potential benefits of lifestyle intervention on incidence and mortality, opportunities exist for the development of community health and nutritional programs aimed at reducing AGE exposure in order to improve breast cancer prevention and treatment outcomes.

Identifiants

pubmed: 30368741
doi: 10.1007/s10549-018-4992-7
pii: 10.1007/s10549-018-4992-7
pmc: PMC6394600
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Biomarkers 0
Glycation End Products, Advanced 0
Receptors, Estrogen 0
Tamoxifen 094ZI81Y45

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

559-571

Subventions

Organisme : NCI NIH HHS
ID : CA176135
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA220736
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210962
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA176135
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210963
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA138313
Pays : United States
Organisme : NCI NIH HHS
ID : CA210962
Pays : United States
Organisme : NCI NIH HHS
ID : CA157071
Pays : United States

Références

J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34
pubmed: 11106684
Diabetologia. 2001 Feb;44(2):129-46
pubmed: 11270668
Cardiovasc Res. 2002 Jun;54(3):649-58
pubmed: 12031711
Ann N Y Acad Sci. 2005 Jun;1043:452-60
pubmed: 16037266
Ann N Y Acad Sci. 2005 Jun;1043:461-6
pubmed: 16037267
J Natl Cancer Inst. 2006 Jul 5;98(13):911-9
pubmed: 16818855
Int J Cancer. 2007 Feb 15;120(4):796-805
pubmed: 17096325
J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):427-33
pubmed: 17452738
Curr Med Chem. 2007;14(15):1653-71
pubmed: 17584071
Breast Cancer Res. 2008;10(5):R88
pubmed: 18928543
J Am Coll Cardiol. 2009 Jun 30;54(1):25-33
pubmed: 19555836
Cancer Res. 2009 Dec 1;69(23):8918-25
pubmed: 19920189
J Am Diet Assoc. 2010 Jun;110(6):911-16.e12
pubmed: 20497781
J Oncol. 2010;2010:739852
pubmed: 20631911
Biomed Khim. 2010 Mar-Apr;56(2):168-78
pubmed: 21341505
Eur J Appl Physiol. 2013 Jan;113(1):147-55
pubmed: 22615009
Breast Cancer Res. 2012 Aug 31;14(4):212
pubmed: 22963717
PLoS One. 2013;8(1):e54078
pubmed: 23342080
Int J Mol Sci. 2012 Dec 20;14(1):108-45
pubmed: 23344024
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
pubmed: 2359136
Biochim Biophys Acta. 2014 Mar;1840(3):1083-91
pubmed: 24252278
Redox Biol. 2014 Jan 09;2:411-29
pubmed: 24624331
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2186-91
pubmed: 25053712
Carcinogenesis. 2015 Jan;36(1):122-32
pubmed: 25421723
Cancer Res. 2015 May 15;75(10):1925-9
pubmed: 25920350
Diabetologia. 2016 Oct;59(10):2181-92
pubmed: 27468708
Adv Cancer Res. 2017;133:1-22
pubmed: 28052818

Auteurs

Katherine R Walter (KR)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Marvella E Ford (ME)

Department of Public Health Sciences, MUSC, Charleston, SC, USA. fordmar@musc.edu.
Hollings Cancer Center, MUSC, Charleston, SC, USA. fordmar@musc.edu.
James E. Clyburn Research Center Medical University of South Carolina, Charleston, SC, 29425, USA. fordmar@musc.edu.

Mathew J Gregoski (MJ)

Department of Exercise Science, College of Arts and Sciences, Campbell University, Buies Creek, NC, USA.

Rita M Kramer (RM)

Hollings Cancer Center, MUSC, Charleston, SC, USA.

Kendrea D Knight (KD)

Department of Public Health Sciences, MUSC, Charleston, SC, USA.

Laura Spruill (L)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Lourdes M Nogueira (LM)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Bradley A Krisanits (BA)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Van Phan (V)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Amanda C La Rue (AC)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Hollings Cancer Center, MUSC, Charleston, SC, USA.
Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA.

Michael B Lilly (MB)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.

Stefan Ambs (S)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

King Chan (K)

Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, USA.

Tonya F Turner (TF)

Dietetic Services, MUSC, Charleston, SC, USA.

Heidi Varner (H)

Department of Public Health Sciences, MUSC, Charleston, SC, USA.

Shweta Singh (S)

Department of Public Health Sciences, MUSC, Charleston, SC, USA.

Jaime Uribarri (J)

Department of Medicine/Renal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Elizabeth Garrett-Mayer (E)

Department of Public Health Sciences, MUSC, Charleston, SC, USA.
Hollings Cancer Center, MUSC, Charleston, SC, USA.

Kent E Armeson (KE)

Department of Public Health Sciences, MUSC, Charleston, SC, USA.
Hollings Cancer Center, MUSC, Charleston, SC, USA.

Ebony J Hilton (EJ)

Department of Anesthesia and Perioperative Medicine, MUSC, Charleston, SC, USA.

Mark J Clair (MJ)

Department of Medicine, Division of Cardiology, MUSC, Charleston, SC, USA.

Marian H Taylor (MH)

Department of Medicine, Division of Cardiology, MUSC, Charleston, SC, USA.

Andrea M Abbott (AM)

Department of Surgery, MUSC, Charleston, SC, USA.

Victoria J Findlay (VJ)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Department of Public Health Sciences, MUSC, Charleston, SC, USA.

Lindsay L Peterson (LL)

Washington University School of Medicine, St. Louis, MO, USA.

Gayenell Magwood (G)

College of Nursing, MUSC, Charleston, SC, USA.

David P Turner (DP)

Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA. turnerda@musc.edu.
Department of Public Health Sciences, MUSC, Charleston, SC, USA. turnerda@musc.edu.
James E. Clyburn Research Center Medical University of South Carolina, Charleston, SC, 29425, USA. turnerda@musc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH